Home > Press > Iroko Pharmaceuticals Acquires Nano-Reformulated Products from iCeutica
Iroko Pharmaceuticals, LLC and iCeutica, Inc. announce Iroko's acquisition of worldwide rights to two products formulated by iCeutica's proprietary Encapsulated Organic Nanoparticle (EON™) Platform technology. In addition, Iroko and iCeutica will collaborate on the application of iCeutica's EON Platform to reformulate an internal proprietary Iroko product. Iroko will guide progression of these EON formulated products through the regulatory process and ultimate launch.
Iroko Pharmaceuticals Acquires Nano-Reformulated Products from iCeutica
Philadelphia, PA | Posted on July 1st, 2007
"We are very pleased to announce this collaboration with iCeutica. The EON formulated products Iroko has acquired can have significant, relevant benefits for patients, in enhancing onset of action and reducing side effects," said Iroko President and CEO, John Vavricka.
"This transaction represents our first major transaction with a Pharmaceutical Company and further validates the value proposition of the EON Platform. Our team is very impressed with Iroko's highly credible and experienced team and looks forward to Iroko driving the first EON reformulated product to market," stated iCeutica CEO, Matt Callahan.
About Iroko Pharmaceuticals, LLC
Iroko is a pharmaceutical company focused on specialty therapeutic areas. The company acquires, develops, and maximizes the potential of currently marketed pharmaceutical products. Iroko increases the revenues of acquired products through focused selling and marketing efforts and product life cycle management activities including development of relevant formulations to improve patient treatment.
About iCeutica Inc: iCeutica commercializes products developed utilizing their proprietary EON™ Platform. EON is an enabling reformulation technology which provides low cost solutions to extend the life cycle of marketed products, as well as to become a cornerstone drug delivery technique for new chemical entities. The EON Platform provides a simple and scalable process to reformulate a range of different drugs.
For more information, please click here
Lisa Gray, Managing Partner
Phoenix IP Ventures
Copyright © Iroko Pharmaceuticals, LLC
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes March 4th, 2015
Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015
Democratizing synthetic biology: New method makes research cheaper, faster, and more accessible March 3rd, 2015
Pens filled with high-tech inks for do-it-yourself sensors March 3rd, 2015
MIG Takes a Roll-Up-Your-Sleeves Approach with Revamped MEMS/Sensors Technical Event -- MIG welcomes technologists to MEMS Technical Congress, emphasizes working groups and breakout sessions on emerging MEMS & sensors, tech transfer and integration March 6th, 2015
Phenom-World announces the Phenom XL, world’s fastest desktop SEM to handle large samples March 6th, 2015
Air Bearing Stage / Systems Introduced by PI at Photonics West March 6th, 2015
Get ready for NanoDays! March 5th, 2015
French Institutes IRT Nanoelec and CMP Team up to Offer World’s First Service for Post-process 3D Technologies on Multi-Project-Wafer March 5th, 2015
American Chemical Society Presidential Symposia: nanoscience, international chemistry March 5th, 2015
Keysight Technologies Shifts to Direct Sales of High-Performance Products in North America March 3rd, 2015
Cambrios and Heraeus Jointly Create New, High-Conductivity Transparent Conductors: Two Companies' Combined Products Dramatically Extend Flexible Substrate Capabilities for Next-Generation Mass-Market Technology Products March 3rd, 2015